Tuesday, November 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· July 4, 2026

Real estate stocks eke out gains in June, post solid returns in four months of H1 2026

View original at seekingalpha.com
Real estate stocks eke out gains in June, post solid returns in four months of H1 2026 [Real estate entrepreneurs meeting to sell a house, discussing real estate deals, with house plans on the table, symbolizing real estate investment and negotiations.] Real estate stocks saw a strong close to the first half of 2026, p…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Expected book value erosion of $0.35-$0.45 per share from frictional costs, and potential further erosion of $0.58-$1.24 per share from asset sales, during the disposal period

    60% confidence

  • Oppenheimer analyst Jason Helfstein maintained a Buy rating on Compass (COMP) with a $15.00 price target after management met with the firm

    60% confidence

  • Citi upgraded American Healthcare REIT to Buy from Neutral, citing relative underperformance as an attractive entry point

    60% confidence

  • Citi cut Sabra Health to Neutral

    60% confidence

  • ARI had roughly $1.3B of cash and $462M of book value tied up in five real estate assets, and it will take 9 to 12 months to fully dispose of the five properties

    60% confidence

  • BTIG downgraded Apollo Commercial Real Estate Finance (ARI) to Neutral from Buy, citing that asset sales are expected to drag on book value

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,558 source documents archived
Query this data → isubstrate.com